Advancing small molecule immunotherapy.
At the leading edge of oncology.
Solving problems that haven’t been solved.
Addressing needs that haven’t been met.
We are developing novel small molecule immunogenic anti-cancer agents. Our lead agent, PT-112, is a highly potent immunogenic cell death (ICD) inducer, currently in Phase 2 clinical development.
Promontory Therapeutics was a 2023 Prix Galien USA Best Startup Nominee
-
Unique Mechanism of Action
-
Single-agent Activity & Demonstrated Safety
-
Synergy with Immune Checkpoint Inhibitors
Learn about our lead clinical drug candidate.
How our agent induces an adaptive immune response.
Why Promontory is different from others.
News and updates.
Have questions?
Reach out to us to learn more about our company, science, potential partnerships or other opportunities.